Breaking News

DryShips Inc. DRYS Stock News

DryShips Inc. (NASDAQ: DRYS)

DryShips is having a very bad day in the market today, only falling further after yesterday’s declines. While the stock was trading in the green at the open, that didn’t last very long. As soon as the trading session started, the stock started to dive, quickly making it to the red and beyond. Below, we’ll talk about what we’re seeing from DRYS, why, and what we’ll be watching for ahead.





What We’re Seeing From DRYS

As mentioned above, DryShips isn’t having the best of days in the market today. In fact, the stock is seeing some big losses. In the pre-market, things looked like they might go well. In fact, the stock opened the day slightly in the green, thanks to strong pre-market activity. Nonetheless, at the open, it took a dive, and it has been falling ever since. At the moment (11:08), DRYS is trading at $2.75 per share after a loss of $0.53 per share (16.16%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas brought the alert to us first about the downward movement on DRYS. As soon as we received the alert, the CNA Finance team started working to see why the stock was falling so hard. The truth is that there has been no fundamental news released that would suggest such strong declines. Nonetheless, we believe we know the reason for the fall.




A short while ago, DryShips announced a $200 million fund raise. While most experts covering the story saw it as incredibly dillutive and not likely to be in the best interest of investors, excitement surrounding the raise sent the stock higher. However, that excitement has died off, and now investors are back to concerns.

At the end of the day, DRYS isn’t in the best position at the moment. Not only is the company likely to hit some major financial headwinds soon, there are also allegations of potential fraud on behalf of the CEO that have been surfacing for weeks. With no new positive news, investors are forced to move based on what they know about the company; unfortunately, that’s not good news for the stock price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DRYS. In particular, we’re watching for an update from the company in an attempt to stop the bleeding. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Update (11:43): DRYS continues on the steady downtrend. Currently, the stock is trading at $2.68 per share after a loss of $0.60 per share (18.45%) thus far today. Considering the rate of the fall, it wouldn’t be unrealistic for the stock to close down between 20% and 25% today. Further declines are likely to come as the bears take charge and the bulls abandon ship!

UPDATE Feb 23, 11:07 – Things don’t seem to be getting any better as DRYS continues the plunge. At the moment, the stock is trading at $2.26 per share after a loss of $0.44 per share or 16.30% thus far today. Considering the momentum, chances are that there is still room to fall!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 610
Alimera Sciences Inc ALIM Stock News

Alimera Sciences Inc (NASDAQ: ALIM)

Alimera Sciences is having an incredibly strong day in the market today. At the opening bell, the stock was trading well into the green before dipping downward back to the break even point in the first few minutes. However, since then, we’ve seen continuous upward movement, driving the stock to impressive gains. Below, we’ll talk about what we’re seeing from ALIM, why, and what we’ll be watching for ahead.





What We’re Seeing From ALIM

As mentioned above, Alimera Sciences is having a great day in today’s trading session. When the session opened for the day, the stock was already trading in the green. Shortly after the open, the stock corrected, falling to the break even point before hitting support and deciding to rocket upward. At the moment (10:47), ALIM is trading at $1.36 per share after a gain of $0.11 per share or 8.48% thus far today.

Why The Stock Is Soaring

As is usually the case, our friends at Trade Ideas were the first to notify us of the upward movement on ALIM. As soon as we got the notification, the CNA Finance team started digging to see exactly why the stock was soaring. It didn’t take long to uncover the story. The gains are the result of news surrounding the FDA.




Early this morning, a press release by the company announced that Health Canada has accepted the company’s New Drug Submission. The submission surrounds ILUVIEN(R) and has been accepted for review. The treatment is designed to treat macular edema in patients who have previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. If approved, the treatment could be overwhelmingly profitable for Alimera Sciences, ultimately, causing exciting among investors.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ALIM. In particular, we’ll be watching the news surrounding the New Drug Submission and of course, hoping for the best. After all, if it is approved, this treatment could lead to tremendous profits for the company and shareholders alike. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Internap Corp INAP Stock News

Internap Corp (NASDAQ: INAP)

Internap is having an incredibly strong day in the market today. As soon as the trading session opened, the stock was already trading dramatically in the green. While we did see a bit of a correction shortly after the bell, it didn’t last long, and now, the stock is headed back upward. Below, we’ll talk about what we’re seeing from INAP, why, and what we’ll be watching for ahead.





What We’re Seeing From INAP

As mentioned above, Internap is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading on impressive gains. While it did correct a bit since then, the stock found support well ahead of the break even point and is currently headed back upward. At the moment (10:08), INAP is trading at $2.69 per share after a gain of $0.88 per share or 48.61% thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on INAP. As soon as we received the notification, the CNA Finance team went to work to see if we could uncover the cause of the movement. In this case, it didn’t take very long. The gains are the result of a fund raising effort that went well.




Internap announced a private placement of about 23.8 million shares early this morning. The shares of common stock sold for a price of $1.81 each, grossing approximately $43 million. The buyers of these shares were a group of investors that includes affiliates of or funds managed by GAMCO Investors as well as accounts advised by Avenir Corporation. In a statement, Peter D. Aquino, President and CEO at INAP had the following to offer…

The confidence demonstrated by our investors in the future of INAP is extremely motivating to the entire management team as we continue our comprehensive operations improvement initiative… The speed with which our new team is moving to right-size our business and invest in sales and marketing to capture strong market demand for Colocation and Cloud Services is impressive. The next steps in the 2017 transformation of the new INAP is to approach the market as two pure plays, complete our debt refinancing, and begin to consider strategic opportunities to bolster organic growth.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on INAP. In particular, we’ll be watching as the company continues on the restructuring process, toward what we believe will be a far more efficient and profitable endpoint. Nonetheless, we’ll keep a close eye on the progress and continue to bring the updates to you as they break!

Update (11:51): INAP is on a slow, yet steady downward path. At the moment it is trading at $2.28 per share. While that is quite a bit lower than it was at the time of this article’s publication, the gains are still impressive, currently at 25.97, and the stock is still likely to close well in the green.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Under Armour Inc Class A UAA Stock News

Under Armour Inc Class A (NYSE: UAA)

Under Armour was off to what seemed like it could have been a rough day in the market today. After starting the day off well into the green, the stock quickly took a dive, making it to the red within the first hour. While it seemed as though all hope was lost for the day, the stock started to spike toward the top minutes ago, quickly making it to the green. Below, we’ll talk about what we’re seeing from UAA, why, and what we’ll be watching for ahead.





What We’re Seeing From UAA

As mentioned above, Under Armour wasn’t having the best of days in the market today. While the stock started the day off in the green, it quickly made a run for the red, making it to the red within the first half hour. However, minutes ago, the stock went from red to green in what seemed like no time at all. Currently (10:14), UAA is trading at $22.07 per share after a gain of $0.29 per share (1.33%) thus far today.

Why The Stock Is Spiking

As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains on UAA. As soon as we received the alert, the CNA Finance team started working to see why the stock was making a run for the top. It didn’t take long to find the reason for the gains. Ultimately, the spike is being caused by a rumor.




At the moment, if you search for Under Armour on your favorite social network, chances are that you will find the rumor too. At the moment, there’s chatter surfacing that the company may be acquired. Now, keep in mind that the rumor is incredibly vague. No one is suggesting who the buyer might be nor at what price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on UAA. In particular, we’re watching to see if there is any validity to the acquisition rumors happening at the moment. After all, if a takeover does happen, it could return tremendous value to shareholders. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 1547
Cemtrex Inc CETX Stock News

Cemtrex Inc (NASDAQ: CETX)

Cemtrex looked like it was going to have a relatively normal day in the market early on. When the opening bell rang, the stock was trading in the green, and throughout about the first 15 minutes, it stayed above the breakeven point. However, minutes ago, the stock started to take a dive. Below, we’ll talk about what we’re seeing from CETX, why, and what we’ll be watching for ahead.





What We’re Seeing From CETX

As mentioned above, Cemtrex seemed to be having a relatively normal start to the trading session today. At the opening bell, the stock was already trading slightly in the green. From there, we saw some upward and some downward movement, but nothing was worth writing home about. That is, until minutes ago when the stock started to spiral downward. Currently (9:53), CETX is trading at $4.71 per share after a loss of $0.41 per share (8.01%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the losses on CETX. As soon as we received the alert, the CNA Finance team started digging to see exactly why the stock was falling. It didn’t take long to uncover the story. At the moment, it seems as though investors are spooked, as allegations have been waged against the company.




We found the allegations via social media, and regardless of which social network is your favorite, you should be able to find them too. All you’ll need to do is search for either “Cemtrex” or “CETX” and the posts should pop up. Unfortunately, any allegations of fraud tend to send stocks sliding out of control, as the allegation is generally the first step toward an investigation and a potentially massive headache for the company.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CETX. In particular, we’ll be digging deeper into the fraud allegations to see if there is any validity to them. We’ll also be watching the story as it unfolds and working to bring you any new developments as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 535
Cellectar Biosciences Inc CLRB Stock News

Cellectar Biosciences Inc (NASDAQ: CLRB)

While it is early on in the market at the moment, that’s not stopping Cellectar Biosciences from seeing gains. At the open of the trading session, the stock was already trading well in the green. The gains are the result of an announcement surrounding a key Phase 1 clinical trial. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for ahead with regard to CLRB.





What We’re Seeing From CLRB

As mentioned above, Cellectar Biosciences is having a relatively strong start to the trading session today. At the open, the stock was already trading well into the green. While we did see some downward movement shortly after the bell, the stock has reached support and is currently headed back upward. At the moment (9:43), CLRB is trading at $2.63 per share after a gain of $0.04 per share or 1.54% thus far today.

Why The Stock Is Headed Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on CLRB. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the upward movement. In this particular case, it didn’t take long to dig up the story. The gains are the result of an announcement surrounding a Phase 1 clinical trial.




Early this morning in pre-market hours, Cellectar Biosciences announced that after successfully completing Cohort 3, the company has no initiated its fourth cohort of its Phase 1 clinical trial of CLR 131. In this cohort, patients will receive 31.25 mCi/m2 of CLR 131 as a single dose infusion. This is a 25% increase from cohort 3. The goal of the Phase 1 study is to establish a maximum tolerated single dose of CLR 131. In a statement, Jim Caruso, president and CEO of CLRB, had the following to offer…

Our enthusiasm for CLR 131’s potential in multiple myeloma patients continues to grow given the positive safety, efficacy markers, progression-free survival and median overall survival results that we have observed to date in the Phase 1 trial, particularly given such a heavy pretreated patient population… We will explore the potential enhanced clinical benefits of a two-dose regimen in our imminent Phase II study, and look forward to updating investors on results of the fourth cohort when available.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLRB. In particular, we’ll be paying close attention to continued progression with regard to CLR-131 and we are excited for the coming results of Phase I, Cohort 4. Nonetheless, we’ll be watching the news closely and we will continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 921
Agenus Inc AGEN Stock News

Agenus Inc (NASDAQ: AGEN)

While the market hasn’t opened quite yet for the day, Agenus isn’t likely to have the best of days. Unfortunately, the stock is falling hard in the pre-market trading hours after announcing that it has stopped patient enrollment into a key study. Below we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to AGEN ahead.





What We’re Seeing From AGEN

As mentioned above, the market hasn’t quite opened yet. Nonetheless, in the pre-market, AGEN isn’t having the best of times at the moment. Shortly after information was released with regard to the ceasing of study enrollment, the stock started to dive. At the moment (9:02), AGEN is trading at $4.30 after a loss of $0.24 per share (5.29%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to notify us of the decliness on AGEN. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to uncover the story. The declines are ultimately the result of news surrounding a clinical study.




In a regulatory filing that was made available today, investors learned that Agenus has stopped the patient enrollment process for a key Phase 2 clinical study. The study is assessing Prophage G-200 in combination with Avastin as a treatment for patients with surgically resectable recurrent glioblastoma multiforme.

The reason that the enrollment was stopped had to do with an interim analysis. The Data Safety and Monitoring Board suggested that the study was not likely to demonstrate a benefit over bevacizumab alone, and if that’s the case, AGEN is better off cutting its losses rather than continuing.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AGEN. In particular, we’ll be watching to see if anything changes with regard to the study mentioned above. We’ll also be watching the company’s ongoing work surrounding other treatments in its pipeline. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Naked Brands Group NAKD Stock News
Naked Brand Group Inc (NASDAQ: NAKD)

Investors who are attracted to emerging companies are not exactly a rare breed, but, for all intents and purposes, they do share some inherent traits that make them somewhat of a renegade spirit in the investment world. Let’s face it, these investors aren’t easily phased by turbulent volatility, are willing to look past transgressions, and for the most part, are willing to undertake a significant risk in order to generate a meaningful reward.

Now, what if there was an emerging story that can offer investors the best of all worlds… a superior management team, a well capitalized balance sheet, and an actual brand that has already established a remarkable footprint worldwide? Would you read that story? If you are not intrigued yet, read on, because investors may soon be treated to witness the process behind the building of a brand, and the real time saga of how an iconic brand like Bendon is going to transform a relatively small company, Naked (NAKD) intimate and innerware apparel, into a national brand capable of defining a new era of the way undergarments are marketed and sold.

Bendon Can Be Naked Too

Some investors are probably already familiar with NAKD apparel, but they may have failed to realize that an investment opportunity was also at hand. Naked is not a new brand of underwear and intimate apparel. In fact, with the label being sold since 2010, they have established a strong and genuine reputation, formalizing engaging relationships with the likes of HSN, Macy’s, Bloomingdale’s, and other major department store chains throughout the United States. But, even well liked and emerging brands, like Naked, eventually need deep pocketed support on their drive toward profitability. And, this is where Bendon plays the critical role in propelling not only NAKD, but their own company as well, perpetuating their iconic name in additional worldwide markets.

Let’s not kid ourselves. While NAKD can deliver additional value and market opportunity to Bendon, the real hero of this story is Bendon, and the proposed deal to merge with Naked Brand Group demonstrates how they can utilize their global company, size, strength and management expertise to bring near term shareholder value to investors that have already bought into the company’s brand story.

Bendon, in its 70 year history, brings enormous opportunity to NAKD shareholders, but Naked Brand Group is contributing some well earned assets as well. For instance, Naked has seen its brand sales grow and has also attracted enormous talent to endorse its men’s line of athleisure wear, with Dwayne Wade serving the endorsement role in the men’s category. And, with Bendon delivering an evergreen partnership agreement with Heidi Klum, the combined marketing power in just the intimate apparel and undergarment segment may continue to prove a lucrative market for Bendon and Naked Brand Group alike. If you are a NAKD shareholder, having an interested partner like Bendon may be equivalent to hitting the jackpot on a one armed bandit.

Let’s be honest, while celebrity endorsements can be bought and paid for on some levels, it doesn’t happen in the case of Klum and Wade. Their endorsements are sincere and powerful, and they deliver a message that both Bendon and Naked brand of underwear and intimate apparel are products worthy of consumer attention. NAKD, for their part, is pioneering a new method of design, using innate features in their line which provides extreme comfort through the use of innovative manufacturing processes, such as “second skin” feeling fabric that is seam free and silver-infused.

Some investors question why Bendon would be so eager to merge with a company like NAKD, whose revenue is less than 2% of Bendon’s trailing twelve months revenue. It’s because Bendon is quick to recognize and seize upon potential. Already enjoying consistent growth, NAKD has engaged in an exclusive partnership for one of its brands with HSN, a premier shopping network that offers a premium showcase for the brand. At the same time, NAKD has positioned the brand to be a specialty garment, allowing for pricing power in an industry where margins have historically been razor thin.

Led by industry veteran Carole Hochman, CEO of Naked Brands, the company has fortified its presence by capitalizing on its management expertise. Banking off of her skill set, NAKD is already positioned to penetrate through the barriers that exist in the apparel industry, barriers that can be prohibitive, especially for companies that are working to develop value through e-commerce and brick and mortar placements. While NAKD, too, has seen its growth hamstrung by small and emerging brands, Bendon offers a competitive advantage by providing NAKD the opportunity to take advantage of the many Bendon distribution channels, allowing the brand a real opportunity for success.

Bendon And The NAKD Truth

The global intimate apparel market is significant, currently being pegged as an $82 billion market. Even more impressive for those keeping score, the already substantial market is expected to grow at a compounded annual growth rate of 17% through the year 2020, keeping the investment opportunity fresh and compelling. Unlike other consumer products, the intimate apparel market has remained relatively strong during economic downturns, in fact, the market even remained stable during the Great Recession. Pockets of growth have been demonstrated for only a small handful of intimate apparel brands, and Bendon has been a worthy inclusion into that select group.

During the past few years, there has been an influx of new and smaller players into the space, facilitated by the relative ease of building a small scale e-commerce site. However, the reality of actually building and maintaining a profitable business strategy beyond the initial launch proves well beyond the reach of most emerging brands, as the customer acquisition costs, lack of an integrated infrastructure, and the barriers in place that can stifle sustainable growth are mostly underestimated by new brands on the block.

Despite the brand and name recognition sometimes enjoyed by small and aspiring brands, in many instances these names only tend to provide a handsome salary to the brand owners, with product sales often unable to provide much of the additional capital required to take a brand beyond the $20 million revenue level.

Without a solid infrastructure and a richly experienced management team in place, the opportunities for growth are minimal, regardless of how well a brand may be received by consumers. In an industry where a single stitching error can cost a company multi-millions of dollars in lost sales and wasted expense, a company that does not launch with a well organized and integrated business plan is often destined to fill the racks at national discount chains. Under Bendon’s tutelage, don’t expect to find NAKD there.

Perhaps Bendon recognized this quality early on in NAKD. Knowing the potential limitations of product and market development for smaller brands, Bendon appears to be taking aim at emerging opportunities to expand its consumer base. For NAKD, by being able to take advantage of Bendon’s significant market position and worldwide distribution platform, the journey forward for investors may prove to be a smooth ride. No doubt, NAKD investors may have hit the jackpot, as a finalized reverse merger will take their investment into a small, 2M revenue company, and facilitate ownership into a much bigger and established worldwide player in Bendon.

Bendon Gets Naked

For NAKD shareholders, the Bendon alliance may be a windfall. Bendon holds a 70 year history deeply rooted in innovation and lifestyle excellence. Its founder is considered a pioneer of modern women’s lingerie, breaking away from styles that included heavy and restrictive corsetry, designing garments that allowed free flow and non-restrictive fits. These innovative features quickly put Bendon on the lingerie map, allowing Australian lingerie to emerge into the competitive arena on the world stage.

Inclusive of Heidi Klum Intimates, Bendon nurtures its own established portfolio of brands, with eight company owned brands and three licensed brands in its stable of intimate apparel and swimwear.

Managing growth, Bendon has a distinguished and experienced executive team, which has built a formidable infrastructure and business operating platform that is conducive to facilitating continuous organic growth as well as the all-important integration of acquisitions.

Bendon’s global distribution and operations platform may turn out to be the perfect fit for NAKD. In January of 2017, NAKD entered into a Letter of Intent with Bendon Limited for a proposed merger of the two companies. Assuming the Merger Agreement is ratified by both boards, the parties expect to seek approval from NAKD shareholders during the first quarter of 2017, subject to SEC review. A merger with Bendon opens the door to tremendous growth and market opportunity for NAKD shareholders and the likelihood of shareholders not endorsing this proposed merger is low. Clearly, the advantages in consummating the deal are a boon for NAKD shareholders, noting that once NAKD is rolled-up, they become part of a much larger and far more powerful company, effectively becoming Bendon.

NAKD Undressed

NAKD is bringing a modest, but consistent record of growth to the table. The company has recorded sales growth in both retail and e-commerce sales, posting a 74% increase in quarter over quarter sales in the third quarter of 2016. Additionally, for the nine months ended October 31, 2016, NAKD’s net sales increased by 38% to $1,292,132, driven primarily by sales expansion into new department stores that include Saks Fifth Avenue, Bloomingdale’s, Chico’s and Dillard’s.

Key partnerships are expected to drive continued growth, utilizing exclusive A-list talent like Dwayne Wade, who will endorse and spearhead their Naked Truth marketing campaign. Taking advantage of Wade’s tremendous social media following, estimated to be in excess of 9 million followers, NAKD capitalized on his social media strengths to launch “Wade x Naked” in October of 2016 at Nordstrom’s, Nordstrom.com, and wearnaked.com. The “Wade x Naked” began generating revenue in the third quarter of 2016.

Investors are anticipating growth in the next financial release, which is expected to show continued traction in all segments of NAKD’s categories.

Bendon Dressed

Bendon, an iconic worldwide brand, is no stranger to delivering impressive financial results. Its global brands include some of the most recognized lingerie brands in Australia, the USA, and the UK. The company has an evergreen partnership in place with Heidi Klum, securing perpetual and mutual benefits, and has maintained focus on its core competencies in the design and development of bras, briefs, swimwear, and sleepwear.

Bendon has demonstrated consistent growth in revenue and earnings, with trailing twelve months revenue (ttm) of $119 million in 2016, and an impressive ttm gross margin of 50.3% of sales. The strong gross margin can be attributed to a host of synergies, but the company’s highly efficient sourcing and logistics network, which provides market agility and economies of scale, acts as the primary bread winner for Bendon.

Bendon’s global footprint has consistently increased over time. The company’s presence is now in 34 countries, with distribution to over 4000 unique customer doors. Additionally, the company benefits from the Omni-channel platform with online, wholesale, and company owned retail and outlet stores peppered throughout its worldwide operations. Sales are generated through a loyal and diverse customer base, with customers ranging in age and social demographic.

Bendon’s brand portfolio is segmented into three categories. The first segment contains its global flagship products,which include Heidi Klum Intimates, Heidi Klum Man, and Heidi Klum Swimwear. These lines secure tremendous online presence through the company’s e-commerce site, and positions the garments as a premium fashion brand for marketing and commercialization purposes. These products offer an accessible price point of between $25 and $99 per item or set.

The company’s “Luxury” segment also enjoys global distribution, with specifically constructed marketing bringing the opulence of the brand to life. Utilizing premium positioning, the Luxury segment sets price points of between $50 and $170 per item or set.

Bendon’s third business segment is its Moderate And Mass category, with the majority of its presence in Australia and New Zealand. For the United States market, Bendon offers its iconic “Fredericks of Hollywood” line of intimate apparel through its online distribution channel. This category provides a dominant heritage market position and sets retail price points between $20 and $69 per item or set.

A Combined Naked Bendon

Bendon will immediately deliver value to NAKD, and NAKD may enjoy expanded revenue and meaningful distribution channels via Bendon. Additionally, Bendon delivers a significant global operations platform, with over 30 production partner facilities across Asia. Company owned distribution centers in New Zealand, the USA, China, and Hong Kong provide outlets to efficiently get products to their respective markets, and with supporting offices in New Zealand, Australia, Hong Kong, the USA, and the UK, logistical issues can be met directly with an executive team that is fluent with each respective market or region.

Dressed For Growth

Already powerful, Bendon can further set the stage to take advantage of significant opportunities generated from the NAKD merger. The merged company expects to initiate an incremental roll-out of additional retail stores across new and existing markets around the globe. Bendon’s distribution channels are anticipated to quickly facilitate an accelerated growth path for NAKD by allowing the efficient global platform to work its magic, expediting brand placement and offering immense logistical support to fuel and manage the projected growth of the NAKD brand.

However, it is not only the business platform that generates the efficiencies. As previously stated, the combined company will take keen advantage of Carole Hochman’s talent, leveraging her expertise to build a compelling sleepwear business, focusing on building organic growth in the company. Additional category launches including resortwear, athleisure, and tween will also be in a position to benefit greatly from Ms. Hochman’s talents.

What may offer the biggest opportunity for the combined business is the fragmented nature of the intimate apparel and swimwear industry globally. The company has been vocal that an acquisitive growth strategy, leveraging the capital market’s platform to consolidate synergistic businesses is critical to its immediate and mid term game plan. In a market that has become highly fragmented due to the relative ease of initial entry, Bendon can utilize its expertise to take advantage of potential roll-up opportunities, and continue to maintain itself in a position to consolidate segments of the industry. In that respect, the company believes that it has identified a potential deal pipeline that can generate in excess of $190 million in incremental revenue opportunity.

While the merged entity will be loaded with extremely valuable and proficient executive talent, an associate described to me the resulting entity to its core, which should cause investors to take an interested and genuine look at the value proposition this deal has to offer.

To paraphrase, he said that if Carole Hochman is placed into a role that allows her to do what she does best, which is building, developing, and acquiring new brands, then there is no limit as to how far Bendon’s acquisitive ambitions can go. Investors should value her involvement, and with the Bendon muscle behind her, the investment opportunities are greatly magnified.

Taking into account all of the positives and accretive synergies to this proposed deal, investors may be well suited in considering an investment into this combined entity. So much so, in fact, that they may even feel eager and excited to join Klum and Wade…and walk around Naked.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I have no position in any stock mentioned, but may initiate a long position in NAKD within the next 72 hours.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 543
Actinium Pharmaceuticals Inc ATNM Stock News

Actinium Pharmaceuticals Inc (NYSEMKT: ATNM)

Actinium pharmaceuticals (ATNM) on Tuesday announced the hiring of Steven Price, to serve as Vice President, Clinical and Commercial Strategy.





Mr. Price, an industry veteran will be responsible for leading the development and optimized programs for Iomab-B, including initiatives targeted at patients, physicians, and payors designated to support clinical development and pre-commercialization efforts.

Key Hiring Adds Depth To An Already Robust Management Team

Mr. Price will bring extensive industry experience to ATNM, delivering over 30 years of marketing and strategic leadership experience to the company. His work specializes in the oncology field with most recent experiences in immunotherapy focused on hematology at Merck and antibody-based therapeutics at Imclone Systems.

Prior to joining the ATNM team, Mr. Price most recently served as the Global Disease Lead at Merck, where he focused on Keytruda, an anti-PD-1 immuno-oncology antibody. In that capacity, he served as the commercial lead on the product development team and was responsible for maximizing physician acceptance, KOL development, market penetration, and new indication launch uptake. Additional experience includes a vast knowledge of pre-launch strategies, pre-market evaluations, strategy development, and strategic and product implementation initiatives.




At Imclone, Mr. Price served as the Associate Vice President, Global New Products Strategic Marketing, where he was responsible and successful at facilitating all commercial aspects of the new product pipeline. Imclone subsequently became a wholly owned subsidiary of Eli Lilly.

Commenting on the hiring, ATNM Executive Chairman, Sandeth Seth, stated, “Steve’s hiring represents another significant step in Actinium’s growth and one that I am most excited about. Steve brings to Actinium a significant amount of knowledge and experience specific to hematology and also has deep relationships that he curated in his 30 years in this field. I look forward to working with Steve and the rest of the Actinium team in building a great company that is focused on improving outcomes for patients.”

ANTM Platform

ATNM is efficiently executing on their clinical initiatives and continue to deliver impressive results. A biopharmaceutical company that is developing innovative targeted therapies for patients with cancers lacking an effective treatment option, ATNM’s proprietary platform is progressing diligently, utilizing monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill these cells safely and effectively.

ATNM’s lead product, Iomab-B is being designed and developed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, most commonly referred to as a bone marrow transplant. Currently, a bone marrow transplant serves as the only current potential cure for patients with blood-borne cancers, which often requires the use of chemotherapeutic treatments and total body irradiation that often results in significant toxicities.

ATNM is progressing in its single pivotal, 150-patient multi-center phase III clinical study of Iomab-B in patients with relapsed or refractory acute multiple myeloma in patients 55 years of age and over. Interim results are expected during 2017.

ATNM has a second promising clinical stage candidate, Actimab-A. Actimab-A is currently advancing its study in a multi-center, open label, 53 patient phase II trial for patients newly diagnosed with AML and are 60 years of age or older. Endpoints for this study are working to demonstrate the ability to induce remissions in elderly patients with AML who lack effective treatment options, especially for patients that may not have the ability to tolerate standard treatment options that introduce toxicities into the body.

Actimab-M, another product candidate, is being developed and studied in patients with relapsed or refractory multiple myeloma in a phase I clinical trial. ATNM is utilizing its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225, that are directed at various cancers that are blood-borne or form solid tumors in the body.

For continued breaking news coverage on Actinium pharmaceuticals, stay with CNA Finance, your source for all things ATNM.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Americann Inc ACAN Stock News

Americann Inc (OTCMKTS: ACAN)

Shares of AmeriCann. Inc. (ACAN) ripped higher by over 30% on Tuesday on news that the company will be included in the markets first proposed cannabis exchange-traded fund, the Emerging AgroSphere ETF.





ACAN closed just two cents off of its 52-week high at a price of $5.42 per share. Volume of ACAN was almost twice its daily average, and the price spike into the close drove the market cap of ACAN past the $100 million mark, settling in at $103.69 million on the day.

In addition to the potential inclusion into the proposed ETF, ACAN also announced that it has been added to the LD Micro Index as of February 1, 2016. The LD Micro Index is designed to give an accurate representation of the intraday activity of microcap stocks in North America.

ACAN And LD Micro Index

Inclusion into the LD Micro Index may bring liquidity to the shares, as the index identifies and includes only about 1000 stocks in the U.S. and Canada that have a market cap of between $50 million and $300 million, and must trade an average daily volume of at least $50,000 over the preceding three months.

Commenting on the inclusion into the LD Micro Index, David Scher, a spokesman for the index , said, “We have been monitoring AmeriCann for some time now and are truly pleased to see them included in the index. This is a company that has performed incredibly well from a business perspective, as well as an investment perspective.”




ACAN And Emerging AgroSphere ETF

ACAN is also expected to enjoy inclusion into the Emerging AgroSphere ETF, with the ETF Managers Group filing an initial registration statement for what could be the first cannabis ETF created for investors in the U.S. markets. The fund is intending to focus on companies in the medical cannabis industry, and will exclude any and all cannabis related companies that are serving non-medical marijuana markets in the U.S., Canada, or any other country until such time that non-medical use of marijuana becomes legal for recreational and discretionary use.

ACAN’s Plan

As CNA Finance covered in February, ACAN is a company focused toward the development and lease back of cultivation based facilities. The company is developing its state-of-the-art, one million square foot cultivation facility on 53 acres of property located in Massachusetts. The Massachusetts Medical Cannabis Center is expected to be the most technologically advanced cultivation center in the country, targeting the increased demand needs for medical grade cannabis in the United States.

Recognized as one of the fasted growing industries in the country by Cowen & Co. , who project the market to eclipse $50 billion in ten years, ACAN is taking advantage of the lack of industry infrastructure by developing cultivation facilities that can address the rising public demand. The Massachusetts center will be the first of several planned cultivation centers within the ACAN growth strategy.

As always, stay focused to CNA Finance for additional breaking news for AmeriCann.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5824
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...